

L-Thyroxine Sodium Salt Pentahydrate: sc-205729



MATERIAL SAFETY DATA SHEET

The Power to Question

1. PRODUCT AND COMPANY IDENTIFICATION

Product Name: L-Thyroxine Sodium Salt Pentahydrate

Product Number: sc-205729

Supplier: Santa Cruz Biotechnology, Inc.
2145 Delaware Avenue
Santa Cruz, CA 95060
800.457.3801 or 831.457.3800

Emergency: ChemWatch
Within the US & Canada: 877-715-9305
Outside the US & Canada: +800 2436 2255 (1-800-CHEMCALL) or call +613 9573 3112

2. COMPOSITION/INFORMATION ON INGREDIENTS

Synonyms : Sodium levothyroxine; 3-[4-(4-Hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]-L-alaninesodium salt; T4;

Formula : $C_{15}H_{10}I_4NNaO_4 \cdot 5H_2O$

Molecular Weight : 888.93 g/mol

<i>CAS-No.</i>	<i>EC-No.</i>	<i>Index-No.</i>	<i>Concentration</i>
Levothyroxine sodium 6106-07-6	200-221-4	—	—

3. HAZARDS IDENTIFICATION

Emergency Overview

OSHA Hazards

Target Organ Effect

Target Organs

Heart, Central nervous system, Thyroid.

HMIS Classification

Health Hazard: 0

Chronic Health Hazard: *

Flammability: 0

Physical hazards: 0

NFPA Rating

Health Hazard: 0

Fire: 0

Reactivity Hazard: 0

Potential Health Effects

Inhalation May be harmful if inhaled. May cause respiratory tract irritation.

Skin May be harmful if absorbed through skin. May cause skin irritation.

Eyes May cause eye irritation.

Ingestion May be harmful if swallowed.

4. FIRST AID MEASURES

If inhaled

If breathed in, move person into fresh air. If not breathing give artificial respiration

In case of skin contact

Wash off with soap and plenty of water.

In case of eye contact

Flush eyes with water as a precaution.

If swallowed

Never give anything by mouth to an unconscious person. Rinse mouth with water.

5. FIRE-FIGHTING MEASURES**Flammable properties**

Flash point no data available

Ignition temperature no data available

Suitable extinguishing media

Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

Special protective equipment for fire-fighters

Wear self contained breathing apparatus for fire fighting if necessary.

6. ACCIDENTAL RELEASE MEASURES**Personal precautions**

Avoid dust formation.

Environmental precautions

Do not let product enter drains.

Methods for cleaning up

Sweep up and shovel. Keep in suitable, closed containers for disposal.

7. HANDLING AND STORAGE**Handling**

Provide appropriate exhaust ventilation at places where dust is formed. Normal measures for preventive fire protection.

Storage

Keep container tightly closed in a dry and well-ventilated place. Recommended storage temperature: -20 °C

Keep in a dry place.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Contains no substances with occupational exposure limit values.

Personal protective equipment**Respiratory protection**

Respiratory protection is not required. Where protection from nuisance levels of dusts are desired, use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).

Hand protection

For prolonged or repeated contact use protective gloves.

Eye protection

Safety glasses

Hygiene measures

General industrial hygiene practice.

9. PHYSICAL AND CHEMICAL PROPERTIES

Form	powder
pH	no data available
Melting point	207 – 210 °C (405 – 410 °F)
Boiling point	no data available
Flash point	no data available
Ignition temperature	no data available
Lower explosion limit	no data available
Upper explosion limit	no data available
Water solubility	no data available

10. STABILITY AND REACTIVITY

Storage stability

Stable under recommended storage conditions.

Materials to avoid

Strong oxidizing agents, Strong acids

Hazardous decomposition products

Hazardous decomposition products formed under fire conditions. – Carbon oxides, nitrogen oxides (NOx), Hydrogen iodide, Sodium oxides

11. TOXICOLOGICAL INFORMATION

Acute toxicity

no data available

Irritation and corrosion

no data available

Sensitisation

no data available

Chronic exposure

IARC: No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by ACGIH.

NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by OSHA.

Reproductive toxicity – rat – Subcutaneous

Maternal Effects: Other effects. Effects on Embryo or Fetus: Other effects to embryo.

Signs and Symptoms of Exposure

Headache, Vomiting, Cardiac irregularities, nervous system effects, Sweating, Fever, To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.

Potential Health Effects

Inhalation May be harmful if inhaled. May cause respiratory tract irritation.

Skin May be harmful if absorbed through skin. May cause skin irritation.

Eyes May cause eye irritation.

Ingestion May be harmful if swallowed.

Target Organs Heart, Central nervous system, Thyroid.,

Additional Information

RTECS: YP2833760

12. ECOLOGICAL INFORMATION

Elimination information (persistence and degradability)

no data available

Ecotoxicity effects

no data available

Further information on ecology

no data available

13. DISPOSAL CONSIDERATIONS

Product

Observe all federal, state, and local environmental regulations.

Contaminated packaging

Dispose of as unused product.

14. TRANSPORT INFORMATION

DOT (US)

Not dangerous goods

IMDG

Not dangerous goods

IATA

Not dangerous goods

15. REGULATORY INFORMATION

OSHA Hazards

Target Organ Effect

DSL Status

This product contains the following components listed on the Canadian NDSL list. All other components are on the Canadian DSL list.

Levothyroxine sodium

CAS-No.: 6106-07-6

SARA 302 Components

SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.

SARA 313 Components

SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

SARA 311/312 Hazards

Chronic Health Hazard

Massachusetts Right To Know Components

No components are subject to the Massachusetts Right to Know Act.

Pennsylvania Right To Know Components

Levothyroxine sodium

CAS-No.: 6106-07-6

New Jersey Right To Know Components

Levothyroxine sodium

CAS-No.: 6106-07-6

California Prop. 65 Components

This product does not contain any chemicals known to State of California to cause cancer, birth, or any other reproductive defects.

16. OTHER INFORMATION

The above information is believed to be correct but does not purport to be complete and should be used only as a guide. The burden of safe use of this material rests entirely with the user.

11/22/2010